Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Why the rapid development of new drugs poses new challenges

Kostas Stamatopoulos • 9 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia

Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development of new drugs in chronic lymphocytic leukemia (CLL). One key issue is affordability and access according to Dr Stamatopoulos. The other issue is linked to the high pace of development of novel drugs concerns adverse events or late events.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Kostas Stamatopoulos

3:19
Translating scientific advances into clinical success in CLL: satellite symposium highlights
Kostas Stamatopoulos • 19 Mar 2022
2:02
The link between the tumor microenvironment & gene expression in CLL
Kostas Stamatopoulos • 19 Mar 2022
1:46
Pathogenesis and transformation in CLL: session highlights
Kostas Stamatopoulos • 19 Mar 2022
2:54
The definition of high-risk CLL
Kostas Stamatopoulos • 19 Mar 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals